April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Dual anti-angiogenic activity of Bevacizumab from its IgG1-Fc domain and VEGF neutralization
Author Affiliations & Notes
  • Takeshi Mizutani
    Ophthalmology & Visual Science, University of Kentucky, Lexington, KY
  • Nagaraj Kerur
    Ophthalmology & Visual Science, University of Kentucky, Lexington, KY
  • Shengjian Li
    Ophthalmology & Visual Science, University of Kentucky, Lexington, KY
  • Younghee Kim
    Ophthalmology & Visual Science, University of Kentucky, Lexington, KY
  • Reo Yasuma
    Ophthalmology & Visual Science, University of Kentucky, Lexington, KY
  • Tetsuhiro Yasuma
    Ophthalmology & Visual Science, University of Kentucky, Lexington, KY
  • Ana Bastos-Carvalho
    Ophthalmology & Visual Science, University of Kentucky, Lexington, KY
  • Benjamin Fowler
    Ophthalmology & Visual Science, University of Kentucky, Lexington, KY
  • Bradley D Gelfand
    Ophthalmology & Visual Science, University of Kentucky, Lexington, KY
  • Jayakrishna Ambati
    Ophthalmology & Visual Science, University of Kentucky, Lexington, KY
  • Footnotes
    Commercial Relationships Takeshi Mizutani, None; Nagaraj Kerur, None; Shengjian Li, None; Younghee Kim, None; Reo Yasuma, None; Tetsuhiro Yasuma, None; Ana Bastos-Carvalho, None; Benjamin Fowler, None; Bradley Gelfand, None; Jayakrishna Ambati, University of Kentucky (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1936. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Takeshi Mizutani, Nagaraj Kerur, Shengjian Li, Younghee Kim, Reo Yasuma, Tetsuhiro Yasuma, Ana Bastos-Carvalho, Benjamin Fowler, Bradley D Gelfand, Jayakrishna Ambati; Dual anti-angiogenic activity of Bevacizumab from its IgG1-Fc domain and VEGF neutralization. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1936.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Bevacizumab has been reported to inhibit angiogenesis in various mouse models, even though it does not recognize mouse Vegfa. The purpose of this study is to evaluate the relative anti-angiogenic activity of Fc and Fab antibody fragments by determining the efficacy of multiple anti-VEGF drugs in mice in the presence of human VEGFA.

Methods: Serum starved Py4 mouse blood endothelial cells were stimulated with mouse Vegfa or human VEGFA to assess Vegfr2 phosphorylation. Bevacizumab or neutralizing anti-mouse Vegfa mAb was added to medium at the same time. We employed C57BL/6J, and hum-X VEGF mice which express a humanized form of VEGFA. Human VEGFA was injected intravitreously in C57BL/6J mice before laser injury. Choroidal neovascularization (CNV) was induced by laser injury in C57BL/6J mice, and volumes were measured 7 days later by confocal evaluation of Griffonia simplicifolia Isolectin B4 staining of RPE-choroid flatmounts. Bevacizumab, ranibizumab, bevacizumab-Fab, bevacizumab-Fc, or human IgG1 was injected into the vitreous humor of mice immediately after laser injury.

Results: Bevacizumab and ranibizumab inhibited Vegfr2 phosphorylation induced by human VEGFA but not by mouse Vegfa. In C57BL/6J mice, CNV was suppressed by bevacizumab, not by ranibizumab (p<0.05 compared with PBS). CNV, augmented by administration of human VEGFA, was suppressed to similar extents by ranibizumab and bevacizumab-Fab and bevacizumab-Fc and human IgG1, and, to a greater extent, by bevacizumab (p<0.05 compared with PBS + human VEGFA). In humanized VEGF mice, CNV volume was suppressed by bevacizumab-Fc, and also by ranibizumab and bevacizumab-Fab, and, to a greater extent, by bevacizumab (p<0.05 compared with PBS).

Conclusions: Our study conclusively demonstrates an unexpected anti-angiogenic function of the Fc fragment of bevacizumab. The angioinhibitory effects by targeting human VEGFA and endogenous mouse Fc receptor pathways, are additive. These data form the basis for novel Fc-based, non-VEGF targeting, therapeutic strategies for treating neovascular AMD.

Keywords: 412 age-related macular degeneration • 748 vascular endothelial growth factor • 609 neovascularization  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×